Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
Ist Teil von
Clinical cancer research, 2006-02, Vol.12 (4), p.1157-1167
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2006
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
To investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on
1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5
to 8 of TP53 by gene sequencing. TP53 mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype
(high grade, large size, node positive cases, and low hormone receptor content) and in women <60 years old. TP53 mutations
within exons 5 to 8 conferred an elevated risk of breast cancer-specific death of 2.27 (relative risk >10 years; P < 0.0001)
compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status,
and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between
TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone
receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations
in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations
have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179
and R248W) seem to be associated with an even worse prognosis. These results, obtained on the largest series analyzed thus
far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could
have potential uses in clinical practice.